<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Ther</journal-id>
<journal-title-group>
<journal-title>Molecular Therapy</journal-title>
</journal-title-group>
<issn pub-type="ppub">1525-0016</issn>
<issn pub-type="epub">1525-0024</issn>
<publisher>
<publisher-name>American Society of Gene &amp; Cell Therapy</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30389355</article-id>
<article-id pub-id-type="pmc">6318701</article-id>
<article-id pub-id-type="publisher-id">S1525-0016(18)30491-X</article-id>
<article-id pub-id-type="doi">10.1016/j.ymthe.2018.10.002</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Gesicle-Mediated Delivery of CRISPR/Cas9 Ribonucleoprotein Complex for Inactivating the HIV Provirus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Campbell</surname>
<given-names>Lee A.</given-names>
</name>
<email>lee.campbell@nih.gov</email>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="corresp" rid="cor1">∗</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Coke</surname>
<given-names>Lamarque M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Richie</surname>
<given-names>Christopher T.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fortuno</surname>
<given-names>Lowella V.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Park</surname>
<given-names>Aaron Y.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Harvey</surname>
<given-names>Brandon K.</given-names>
</name>
<email>bharvey@mail.nih.gov</email>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="corresp" rid="cor2">∗∗</xref>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label>Intramural Research Program, National Institute on Drug Abuse, Biomedical Research Center, Suite 200, 251 Bayview Boulevard, Baltimore, MD 21224, USA</aff>
<author-notes>
<corresp id="cor1"><label>∗</label>Corresponding author: Lee A. Campbell, Intramural Research Program, National Institute on Drug Abuse, Biomedical Research Center, Suite 200, 251 Bayview Blvd., Baltimore, MD 21224, USA. <email>lee.campbell@nih.gov</email></corresp>
<corresp id="cor2"><label>∗∗</label>Corresponding author: Brandon K. Harvey, Intramural Research Program, National Institute on Drug Abuse, Biomedical Research Center, Suite 200, 251 Bayview Blvd., Baltimore, MD 21224, USA. <email>bharvey@mail.nih.gov</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>02</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>11</day>
<month>10</month>
<year>2018</year>
</pub-date>
<volume>27</volume>
<issue>1</issue>
<fpage>151</fpage>
<lpage>163</lpage>
<history>
<date date-type="received">
<day>8</day>
<month>3</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>8</day>
<month>10</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© 2018 The American Society of Gene and Cell Therapy.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>The American Society of Gene and Cell Therapy</copyright-holder>
</permissions>
<abstract id="abs0010">
<p>Investigators have utilized the CRISPR/Cas9 gene-editing system to specifically target well-conserved regions of HIV, leading to decreased infectivity and pathogenesis <italic>in vitro</italic> and <italic>ex vivo</italic>. We utilized a specialized extracellular vesicle termed a “gesicle” to efficiently, yet transiently, deliver Cas9 in a ribonucleoprotein form targeting the HIV long terminal repeat (LTR). Gesicles are produced through expression of vesicular stomatitis virus glycoprotein and package protein as their cargo, thus bypassing the need for transgene delivery, and allowing finer control of Cas9 expression. Using both NanoSight particle and western blot analysis, we verified production of Cas9-containing gesicles by HEK293FT cells. Application of gesicles to CHME-5 microglia resulted in rapid but transient transfer of Cas9 by western blot, which is present at 1 hr, but is undetectable by 24 hr post-treatment. Gesicle delivery of Cas9 protein preloaded with guide RNA targeting the HIV LTR to HIV-NanoLuc CHME-5 cells generated mutations within the LTR region and copy number loss. Finally, we demonstrated that this treatment resulted in reduced proviral activity under basal conditions and after stimulation with pro-inflammatory factors lipopolysaccharide (LPS) or tumor necrosis factor alpha (TNF-α). These data suggest that gesicles are a viable alternative approach to deliver CRISPR/Cas9 technology.</p>
</abstract>
<abstract abstract-type="teaser" id="abs0015">
<p>In this manuscript, Dr. Campbell and colleagues utilized small, “virus-like” particles called gesicles to deliver Cas9 ribonucleoprotein and target integrated HIV genomes. This pharmacological approach to transiently provide CRISPR-based genome editing to cells resulted in mutation and excision of an HIV provirus in a microglial cell line.</p>
</abstract>
<kwd-group id="kwrds0010">
<title>Keywords</title>
<kwd>gesicle</kwd>
<kwd>Cas9 ribonucleoprotein</kwd>
<kwd>HIV</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>